Rhenium (186Re) obisbemeda (rhenium nanoliposome,186RNL) for the treatment of leptomeningeal metastases (LM): Summary of the phase 1 dose escalation study and phase 2 administered dose selection (SNO 2024) - Nov 7, 2024 - Abstract #CTNI-63; Pres time: Nov 22, 2024; 07:30 PM - 09:30 PM; Location: Hall B3; "A single dose of 186RNL for patients with LM has been well-tolerated, with high absorbed doses to the treatment area, acceptable organ doses, and promising clinical improvement and reductions in tumor cell count. Phase 2 is expected to begin enrollment by Q4 2024. Additionally, based on these data, a Phase 1 multidose study is planned to be initiated this year."
P1 data • P2 data • Melanoma • Oncology • Solid Tumor
|
|
Andrew Brenner; Michael Youssef; Priya Kumthekar; Ande Bao; Joel Michalek; William Phillips; Toral Patel; John Floyd; Marc Hedrick; Leonardo Juverdianu; Barbara Blouw; Norman LaFrance; Melissa Moore
|